Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azilsartan vs Telmisartan on Insulin Resistance in Hypertension with T2DM
NCT02079805Phase 4Completed
- Sponsor
- Takeda
- Start
- Jun 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of azilsartan in essential hypertension (2 arms), sponsored by Takeda. Primary endpoint: Change in Insulin Resistance Index (HOMA-R) at 12 weeks. Started Jun 2014; status: completed.
02
Drugs
azilsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02079805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079805.